Osteologix to Present at 8th Annual Bio Investor Forum

GLEN ALLEN, Va.--(BUSINESS WIRE)--Osteologix, Inc. (OTCBB: OLGX) today announced that Philip J. Young, President and CEO of Osteologix, will present a corporate overview and update at the 8^th Annual Bio Investor Forum being held this week at the Palace Hotel in San Francisco, California. Osteologix’s presentation will take place at 9:00 a.m. ET on Thursday, October 29, in the Pacific Heights room.

About Osteologix

Osteologix is a specialty biopharmaceutical company committed to improving the health of those afflicted with musculoskeletal diseases, such as osteoporosis, by developing innovative therapies. Its lead investigational product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.

For more information on BIO Investor Forum conference please visit: http://investorforum.bio.org/opencms/bif/2009/index.jsp